Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ciclesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Azurity Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Azurity Pharmaceuticals Completes Acquisition of Covis Pharma
Details : Through the acquisition, Azurity will expand its therapeutic portfolio by integrating Covis' product and pipeline, including Alvesco (ciclesonide) for the treatment of asthma.
Product Name : Alvesco
Product Type : Steroid
Upfront Cash : Undisclosed
March 14, 2025
Lead Product(s) : Ciclesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Azurity Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Ciclesonide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ciclesonide is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
May 06, 2020
Lead Product(s) : Ciclesonide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciclesonide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Japan Trials Asthma Drug Alvesco To Fight COVID-19
Details : Institut Pasteur Korea has confirmed the effectiveness of AstraZeneca's ciclesonide in treating COVID-19 in a drug repositioning study by testing over 3,000 agents with infected cells.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
March 28, 2020
Lead Product(s) : Ciclesonide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable